Spectrins are a family of cytoskeletal proteins that organize and link membranes to subcellular motors and filaments. Although traditionally divided into erythroid and non-erythroid forms, the discovery of new spectrin isoforms in various tissues indicates that their distribution is not yet fully characterized. To our knowledge, there is no comprehensive analysis of spectrins in lymphoid malignancies. Using tumor microarrays of paraffin blocks, we immunohistochemically studied 10 lymph nodes with reactive lymphoid hyperplasia and 94 lymph nodes involved by B-cell malignant lymphoma. Expression of spectrins aI, aII, bI, bII, and bIII was scored using a 20% cutoff for positive immunoperoxidase staining. All spectrin isoforms, except erythroid-specific aI spectrin, were detected in lymph nodes with reactive lymphoid hyperplasia. In contrast, various spectrins were lost in particular B-cell malignant lymphomas. Based on the absence of staining for one or more spectrin isoforms in at least 50% of cases, we identified three patterns: (1) loss of aII and bII in follicular lymphoma, grades 2/3 and 3/3; nodular lymphocyte predominance Hodgkin's lymphoma; nodular sclerosis Hodgkin's lymphoma; (2) loss of bI only in Burkitt lymphoma; and (3) loss of aII and bI in mixed cellularity Hodgkin's lymphoma. In contrast, follicular lymphoma, grade 1/3 and diffuse large B-cell lymphoma retained spectrin in 67-100% of cases. The other lymphoma subtypes retained spectrin in greater than 50% of cases. We identified the loss of particular spectrin isoforms in B-cell malignant lymphomas that have a nodular growth pattern and/or are believed to arise from germinal center B-cells, that is follicular lymphoma, grades 2/3 and 3/3; Burkitt lymphoma; nodular sclerosis Hodgkin's lymphoma; mixed cellularity Hodgkin's lymphoma; and nodular lymphocyte predominance Hodgkin's lymphoma. The absence of particular spectrin isoforms may correlate with transformation or aggressive biologic behavior for some lymphoma subtypes.
Spectrin genes have been found in the genomes of metazoans (Drosophila melanogaster, Caenorhabditis elegans, and vertebrates), but not in yeast (Saccharomyces cerevisiae).
1 As unicellular organisms developed into multicellular organisms, a short ancestral a-actinin gene transformed via duplications and rearrangements into the spectrin superfamily. 2 As metazoans evolved specialized cell types, spectrin molecules adapted to the challenges of mechanical stress, subcellular partitioning, cellto-cell communication, and cellular orientation in complex tissue architecture. 1 Spectrins are large, rod-like, multifunctional proteins composed of a-and b-subunits. In humans, two a-subunits (aI, aII) and five b-subunits (bI, bII, bIII, bIV, bV) form various heterodimers. Although aI spectrin is restricted to erythrocytes, the other spectrin isoforms are widespread. 3 Actin-binding domains connect spectrin to the cytoskeleton, forming a bridge between the membrane and the subcellular motors, the filaments, and the rest of the cellular microenvironment. 1 The spectrin isoforms localize to subplasma membrane (aI, aII, bI, and bII), cytoplasmic vesicle (bI and bIII), Golgi apparatus (bI and bIII), 4 and sarcolemma (aII). 5, 6 Mutations in spectrins aI and bI cause hereditary elliptocytosis, poikilocytosis, and spherocytosis. As spectrins are scaffolding proteins, they could play a role in lymphomagenesis either by interfering with signal transmission from the external environment to the cytoskeleton or by aberrantly localizing various kinases or phosphatases that dock to spectrin. 4, 7 To our knowledge, the various spectrin isoforms have not been previously investigated in a comprehensive panel of B-cell malignant lymphomas.
Materials and methods

Lymphoma Samples and Clinical Data
We retrospectively studied spectrin expression in 10 lymph nodes with reactive lymphoid hyperplasia and in 94 lymph nodes with B-cell malignant lymphoma, including follicular lymphoma, grades 1/3 (N ¼ 10), 2/3 (N ¼ 7), and 3/3 (N ¼ 7); Burkitt lymphoma (N ¼ 5); diffuse large B-cell lymphoma (N ¼ 6); B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (N ¼ 15); mantle cell lymphoma (N ¼ 6); marginal zone B-cell lymphoma (N ¼ 11); nodular sclerosis Hodgkin's lymphoma (N ¼ 10); mixed cellularity Hodgkin's lymphoma (N ¼ 9); and nodular lymphocyte predominance Hodgkin's lymphoma (N ¼ 8). The paraffin blocks were retrieved from the files of the Department of Pathology at Montefiore Medical Center (Bronx, NY, USA). Clinical data were obtained from the medical record or the patient's physician. The Institutional Review Board of Montefiore Medical Center (Bronx, NY, USA) has granted permission for us to use clinical information and archival patient tissue samples for research purposes.
Tissue Microarrays
Tissue microarrays were constructed from formalinfixed, paraffin-embedded tissue blocks using a manual tissue arrayer (Beecher Instruments, Silver Spring, MD, USA). To ensure adequate sampling, each case was represented in triplicate using 1.0 mm cores.
Immunohistochemistry
Conditions for immunoperoxidase staining of spectrins aI, aII, bI, bII, and bIII in paraffin tissue sections are listed in Table 1 . Staining for a particular spectrin isoform was considered positive if it was expressed by at least 20% of the neoplastic cells. The subcellular localization was recorded as submembranous, cytoplasmic, or perinuclear dot-like. Positive control tissues included reactive tonsil, kidney, liver, and the Jurkat T-cell leukemia cell line. The spectrin isoforms aII and bII were generally easy to score because of their distinct submembranous staining pattern, which could be detected even at low-power magnification. On the other hand, spectrin isoforms bI and bIII often required either high-power magnification or a Â 100 oil immersion objective, particularly for reactive background lymphocytes. In addition, detection of bI and bIII spectrins sometimes required focusing up and down at different subcellular planes so as not to miss small aggregates of cytoplasmic vesicular or perinuclear dot-like staining.
Results
Spectrin Expression in Non-Neoplastic Cells
In 10 lymph nodes with reactive lymphoid hyperplasia (Figure 1a) , both T cells and B cells expressed aII, bI, bII, and bIII spectrins (Tables 2 and 3 ). The aII and bII spectrins stained more intensely in the paracortical T-zone than in the B-cell follicle ( Figure  1b) . Tingible-body macrophages in the germinal center expressed bI and bIII spectrin isoforms, but lacked aII and bII; the absence of aII-and bII-staining in the histiocytes sharply contrasted with the surrounding uniformly positive lymphocytes (Figure 1b and c) . Although impossible to identify in reactive lymph nodes (Figure 1b and c) or in Bcell malignant lymphomas that expressed spectrin (Figure 1d ), the elongated cellular processes of residual reactive follicular dendritic cells could be easily seen against a background of spectrin-negative lymphoma cells ( Figure 1e and f) ; the follicular dendritic cells expressed aII, bI, bII, and bIII spectrin isoforms. As expected, all lymphoid cells, whether reactive or neoplastic, lacked erythroid-specific aI spectrin (Table 2) .
Spectrin Expression in Neoplastic B-Cells
We immunohistochemically evaluated the expression of aI, aII, bI, bII, and bIII spectrin isoforms in 94 cases of B-cell malignant lymphomas representing 11 different diagnostic categories ( Table 2 ; Figures 1-3 ). Cases were classified as positive if at least 20% of the lymphoma cells expressed a particular spectrin isoform. Six types of B-cell malignant lymphoma ( Figure  3 ) lost at least one spectrin isoform in 50% or more of cases: follicular lymphoma, grades 2/3 and 3/3; Burkitt lymphoma; mixed cellularity Hodgkin's lymphoma; nodular sclerosis Hodgkin's lymphoma; nodular lymphocyte predominance Hodgkin's lymphoma ( Table 2 ; Figure 3 ). The affected cells included both centrocytes and centroblasts in follicular lymphoma, grades 2/3 and 3/3; all neoplastic B-cells in Burkitt lymphoma; Reed-Sternberg cells in mixed cellularity Hodgkin's lymphoma and in nodular sclerosis Hodgkin's lymphoma; and lymphocytic and/or histiocytic variant cells (so-called 'popcorn' cells) in nodular lymphocyte predominance Hodgkin's lymphoma. Thus, lymphoma cells with medium to large size or bizarre shape tended to lose expression of various spectrin isoforms. An interesting exception to this observation was diffuse large B-cell lymphoma, which generally preserved spectrin expression, possibly because these were de novo cases that did not arise by transformation from pre-existing follicular lymphoma. In contrast, none of the B-cell malignant lymphomas composed of small lymphocytes, which varied minimally from the cytologic features of normal lymphocytes, had significant spectrin deficits, that is B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma; mantle cell lymphoma; marginal zone B-cell lymphoma; or follicular lymphoma, grade 1/3.
Subcellular Distribution of Spectrin Isoforms
In all spectrin-positive cases, we confirmed the subcellular distribution of the various spectrin isoforms. 4 aII and bII spectrins localized to the submembranous region, which was best seen in reactive interfollicular T cells and in reactive mantle zone B cells (Figure 1 ), but also in a variety of B-cell malignant lymphomas (Figure 3 ). bI and bIII spectrins occurred in diffuse cytoplasmic and in perinuclear dot-like patterns, which were especially well seen in mixed cellularity Hodgkin's lymphoma (Figure 3p ) and in nodular sclerosis Hodgkin's lymphoma (Figure 3r and t) .
Spectrin Expression in Non-Neoplastic Background Lymphocytes
We semiquantitatively compared the expression of spectrin isoforms aII, bI, bII, and bIII in the lymphocytes of reactive lymphoid hyperplasia vs the background lymphocytes of mixed cellularity Hodgkin's lymphoma, nodular sclerosis Hodgkin's lymphoma, and nodular lymphocyte predominance Hodgkin's lymphoma (Table 3 ). In reactive lymphoid hyperplasia, Z20% of the lymphocytes stained positively for spectrin isoforms bI and bIII, and 450% stained positively for aII and bII. In 67-100% of the cases of mixed cellularity Hodgkin's lymphoma, nodular sclerosis Hodgkin's lymphoma, and nodular lymphocyte predominance Hodgkin's lymphoma, Z20% of the background lymphocytes stained positively for aII spectrin. In contrast, the background lymphocytes expressed bI spectrin at this level in only 45% of the mixed cellularity Hodgkin's lymphoma cases, and in none of the nodular sclerosis Hodgkin's lymphoma or nodular lymphocyte predominance Hodgkin's lymphoma cases. For bII and bIII spectrins, Z20% of the background lymphocytes stained positively in all mixed cellularity Hodgkin's lymphoma and nodular lymphocyte predominance Hodgkin's lymphoma cases, but in no nodular sclerosis Hodgkin's lymphoma cases. As can be seen in Table 3 , the background lymphocytes of mixed cellularity Hodgkin's lymphoma, nodular sclerosis Hodgkin's lymphoma, and nodular lymphocyte predominance Hodgkin's lymphoma tended to be either predominantly positive (450%) or predominantly negative (o20%) for the expression of a particular spectrin isoform. And, in contrast to the lymphocytes of reactive lymphoid hyperplasia, the background lymphocytes of Hodgkin's lymphoma rarely expressed an intermediate range of spectrin (20-50%; Table 3 ).
Discussion
Spectrin isoforms have been extensively characterized in peripheral blood leukocytes, 4 in the nervous system, 8 and in cardiac 6, 9 and skeletal muscle. 5 However, little is known about their distribution in B-cell malignant lymphomas, other than for a few limited studies in chronic lymphocytic leukemia and hairy cell leukemia, 10,11 which employed xenoantisera raised against chicken erythrocyte spectrin. Alterations in spectrin organization following chemotherapy for leukemia, plus the many biochemical connections between spectrin and other molecules throughout the cell, suggest that a wide variety of influences could affect spectrin distribution in normal and neoplastic lymphoid cells. 10, 12, 13 In the current immunohistochemical study, we have used antihuman monoclonal antibodies wherever available to analyze spectrin expression in reactive lymphoid hyperplasia and in a comprehensive panel of B-cell malignant lymphomas. We report the expression of aII, bI, bII, and bIII spectrin isoforms in non-neoplastic T cells, B cells, and follicular dendritic cells. Also, we detected bI and bIII, but neither aII nor bII, spectrin isoforms in tingible-body macrophages. As expected, both reactive lymphoid hyperplasia and B-cell malignant lymphoma lacked erythroid-specific aI spectrin.
We identified frequent absence of particular spectrin isoforms in 6 out of 11 B-cell malignant lymphoma subtypes. Spectrin loss occurred in three unique combinations: bI only (Burkitt lymphoma); aII and bI (mixed cellularity Hodgkin's lymphoma); and aII and bII (follicular lymphoma, grades 2/3 and 3/3; nodular sclerosis Hodgkin's lymphoma; nodular lymphocyte predominance Hodgkin's lymphoma). In the cases of either classic or lymphocyte predominance Hodgkin's lymphoma, it was either the Reed-Sternberg cells or the lymphocytic and/or histiocytic variant cells that were affected. In contrast, all B-cell malignant lymphoma subtypes maintained expression of bIII spectrin. Although several lymphoma subtypes failed to express two There is expression of aII, bI, bII and bIII spectrin isoforms in the lymphoma cells. (e-h) Follicular lymphoma, grade 3/3. In contrast to follicular lymphoma, grade 1/3, the neoplastic B-cells of follicular lymphoma, grade 3/3 expressed neither aII-nor bII-spectrins (e, g). Spectrinpositive non-neoplastic follicular dendritic cell processes can be seen highlighted against spectrin-negative neoplastic B-cells (g). bI and bIII spectrins (f, h) appear similar in both percent of positive neoplastic B cells and in staining intensity. bIII spectrin is localized in strongly positive peri-nuclear dot-like aggregates (h). different spectrins, no single case lost three isoforms. To our knowledge, these findings have not been previously reported.
We also noted the curious finding that, compared to the lymphocytes in reactive lymphoid hyperplasia, the background lymphocytes in some cases of classic Hodgkin's lymphoma and in nodular lymphocyte predominance Hodgkin's lymphoma appeared to downregulate spectrin. As a-interferon is known to affect spectrin in lymphocytes, 10 it is possible that other cytokines and chemokines, which are abundant in the Hodgkin's lymphoma environment, 14, 15 might regulate spectrin. Furthermore, there are numerous CD4 þ /FOXP3 þ regulatory T cells in classic HL, which secrete interleukin-10, 16 and many CD4 þ /CD57 þ T cells in nodular lymphocyte predominance Hodgkin's lymphoma that are unlike the vast majority of lymphocytes found in reactive lymphoid hyperplasia with respect to their suppressive immune function 17, 18 and unique cytokine profile. 19 The presence or absence of spectrin isoforms could be helpful in solving several common problems in lymph node pathology such as confirming the identity of Reed-Sternberg cells in classic Hodgkin's lymphoma, 20 particularly in cases with a dense lymphocytic infiltrate; confirming the identity of lymphocytic and/or histiocytic variant cells in nodular lymphocyte predominance Hodgkin's lymphoma, 21 based on the loss of various spectrin isoforms in classic Hodgkin's lymphoma or in nodular lymphocyte predominance Hodgkin's lymphoma, but not in diffuse large B-cell lymphoma; distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma, 22, 23 based on the frequent loss of bI spectrin in Burkitt lymphoma, but not in diffuse large B-cell lymphoma; and grading follicular lymphomas, 24 which tended to lose aII and bII spectrin isoforms in grades 2 and 3 more often than in grade 1. To establish the value of spectrin isoforms in differential diagnosis would require more cases than in the current survey.
We wondered, could the loss of spectrin isoforms in various B-cell malignant lymphomas be due to a generalized, non-targeted effect of genome-wide instability? The SPTAN1, SPTB, SPTBN1, and SPTBN2 genes, which code for the aII, bI, bII, and bIII spectrin isoforms, map to chromosomal loci 9q34.11, 14q24.1-q24.2, 2p21, and 11q13.2.
2 A literature search for recurrent deletions at these sites did not reveal any. 25, 26 Furthermore, genomic instability is considered rare in B-cell malignant lymphomas. Even microsatellite instability, a type of genomic instability secondary to defective DNA mismatch repair, has only occasionally been detected during progression or histologic transformation of B-cell malignant lymphomas. [27] [28] [29] And evidence for a mutator mechanism of genomic instability in B-cell malignant lymphomas seems to be limited to a small group of genes that are also the sites of recurrent chromosomal translocations. 30 None of these included the spectrin genes. Although recurrent deletions in spectrin genes have not been identified in lymphomas, other gene silencing mechanisms such as DNA hypermethylation, point mutations, transcriptional repression, or RNA interference could result in altered spectrin expression.
Alternatively, we asked, how could the loss of spectrin isoforms possibly contribute to lymphomagenesis? Several pathogenetic mechanisms involving spectrin can be theorized by interfering with spectrin nuclear scaffolding that binds gene regulatory machinery 31 or enhances repair of DNA interstrand crosslinks; 32 interfering with signal transduction that passes through spectrin, 33 which can function as an adaptor molecule, 2,7 from the external environment to the nucleus and causing abnormalities in the cell cycle; 34 or permitting various kinases or phosphatases 4 that dock to spectrin to become untethered 7 and mislocalized to aberrant subcellular sites where they could act on unnatural substrates.
Although most somatic mutations in cancer are passengers that are unnecessary for neoplastic transformation, new and unexpected driver mutations continue to be discovered. 35, 36 We believe that our data are highly suggestive of a heretoforeunsuspected connection between spectrin expression and lymphomagenesis. This is based on the patterns of spectrin loss that affect some, but not all, B-cell malignant lymphomas and the lack of expression of specific isoforms in particular lymphoma subtypes. Nevertheless, definitive proof of a causal link between loss of spectrin expression and lymphomagenesis must await additional studies that are beyond the scope of the current investigation.
